News

Webinar on Community Engagement in MDR-TB Clinical Trials on December 6th

On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials.

It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB, followed by a question and answer session.

 

The presentation will highlight the importance and objectives of community engagement in clinical research, how to implement community engagement before a trial begins, as well as how to bring community engagement into an existing trial. To join the webinar, click here.

 

A recording of the webinar and slides will be available on the TREAT TB website approximately one week after the webinar.

 

TREAT TB’s MDR-TB clinical trial capacity building webinar series will continue over the coming months, with webinars scheduled for January, March, and May 2019.

Future topics to be addressed include regulatory requirements, institutional review boards and ethics approval, as well as laboratory strengthening.

 

More News
9 Jul 2020
Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...